Company research
Immix Biopharma, Inc.
CIK 1873835Updated Sep 26, 2026
SecurityIMMX · NASDAQ · equity
Name history
Immix Biopharma, Inc. · through Aug 14, 2026
IMMX price & chart
Loading TradingView…
NASDAQ:IMMX on TradingView ↗In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX ↗
Recent filings
10-Q filing
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07
4 filing
4 filing
Show 5 more recent filings
4 filing
Other Events
Items 8.01, 9.01
424B5 filing
FWP filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 104,840,341Source | 22,947,872Source | 19,925,160Source | 14,908,101Source |
| Property, Plant and Equipment, NetUSD | 2,521,621Source | 1,740,149Source | 50,181Source | 3,560Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 93,928,566Source | 17,681,954Source | 17,509,791Source | 13,436,714Source |
| Assets, CurrentUSD | 101,237,755Source | 20,197,834Source | 19,787,750Source | 14,897,817Source |
| Prepaid Expense and Other Assets, CurrentUSD | 828,329Source | 541,510Source | 1,105,776Source | 1,205,398Source |
| Operating Lease, Right-of-Use AssetUSD | 966,917Source | 989,471Source | — | — |
| Other Assets, NoncurrentUSD | 20,418Source | 20,418Source | — | 6,724Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,044,171Source | 9,696,669Source | 3,721,783Source | 1,748,296Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 5,301Source | 2,762Source | 2,000Source | 1,397Source |
| Additional Paid in CapitalUSD | 198,293,956Source | 88,374,131Source | 69,779,706Source | 51,156,597Source |
| Retained Earnings (Accumulated Deficit)USD | -104,463,284Source | -75,024,671Source | -53,411,295Source | -37,985,247Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 60,160Source | -1,056Source | 134,666Source | 87,021Source |
| Stockholders' Equity Attributable to ParentUSD | — | 13,251,203Source | 16,405,114Source | — |
| Liabilities and EquityUSD | 104,840,341Source | 22,947,872Source | 19,925,160Source | 14,908,101Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,110,546Source | 8,687,118Source | 3,721,783Source | 1,273,296Source |
| Operating Lease, Liability, CurrentUSD | 139,339Source | 65,219Source | — | — |
| Accounts Payable, CurrentUSD | 5,442,737Source | 5,388,494Source | 1,433,022Source | — |
| Operating Lease, Liability, NoncurrentUSD | 933,625Source | 1,009,551Source | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | -201,737Source | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 100,400,000Source | — | — | — |
| Short-term InvestmentsUSD | 6,480,860Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -29,438,613Source | -21,698,363Source | -15,595,522Source | -8,229,713Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,441,875Source | 3,020,573Source | 2,565,708Source | 524,069Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -23,930,304Source | -14,595,102Source | -11,371,438Source | -7,408,303Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -7,213,785Source | -1,177,680Source | -52,089Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 732,925Source | 1,177,680Source | 52,089Source | — |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | — | 99,963Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 107,386,859Source | 15,948,567Source | 15,463,512Source | 3,232,063Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 76,246,612Source | 172,163Source | 4,073,077Source | -4,207,764Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 9,596Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,842Source | -3,622Source | 33,092Source | -31,524Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 731,329Source | 476,746Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 100,400,000Source | — | — | — |
| DepreciationUSD | 245,747Source | 32,941Source | 5,468Source | 2,135Source |
| General and Administrative ExpenseUSD | 13,697,817Source | 11,381,978Source | 7,406,082Source | 4,023,170Source |
| Income Tax Expense (Benefit)USD | 37,724Source | 41,037Source | 26,415Source | 10,268Source |
| Investment Income, InterestUSD | 555,526Source | 1,017,354Source | 572,006Source | — |
| Net Income (Loss) Attributable to ParentUSD | -29,438,613Source | -21,613,376Source | -15,426,048Source | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | -84,987Source | -169,474Source | — |
| Nonoperating Income (Expense)USD | 555,526Source | 1,017,354Source | 572,006Source | -497Source |
| Operating ExpensesUSD | 29,956,415Source | 22,674,680Source | 16,141,113Source | 8,218,948Source |
| Proceeds from Issuance of Common StockUSD | 107,392,716Source | 15,946,078Source | 15,520,510Source | 2,913,750Source |
| Proceeds from Stock Options ExercisedUSD | 6,342Source | — | 2,618Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -29,956,415Source | -22,674,680Source | -16,141,113Source | -8,218,948Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -29,400,889Source | -21,657,326Source | -15,569,107Source | -8,219,445Source |
| Income Tax Expense (Benefit)USD | 37,724Source | 41,037Source | 26,415Source | 10,268Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | -84,987Source | -169,474Source | — |
| Net Income (Loss) Attributable to ParentUSD | -29,438,613Source | -21,613,376Source | -15,426,048Source | — |
| Earnings Per Share, BasicUSD per share | -0.89Source | -0.76Source | -0.89Source | -0.59Source |
| Earnings Per Share, DilutedUSD per share | -0.89Source | -0.76Source | -0.89Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 32,965,706Source | 28,285,637Source | 17,341,146Source | 13,887,309Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 32,965,706Source | 28,285,637Source | 17,341,146Source | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 13,697,817Source | 11,381,978Source | 7,406,082Source | 4,023,170Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -29,101,560Source | -20,114,816Source | 13,952,065Source | 7,741,995Source |
| Interest ExpenseUSD | — | — | — | 497Source |
| Investment Income, InterestUSD | 555,526Source | 1,017,354Source | 572,006Source | — |
| Nonoperating Income (Expense)USD | 555,526Source | 1,017,354Source | 572,006Source | -497Source |
| Operating ExpensesUSD | 29,956,415Source | 22,674,680Source | 16,141,113Source | 8,218,948Source |
| Research and Development ExpenseUSD | 16,258,598Source | 11,292,702Source | 8,735,031Source | 4,195,778Source |
Filing attachments
ex99-1.htm · 8-K · 2026-05-21
EX-99.1 4 ex99-1.htm EX-99.1 Exhibit 99.1 Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock LOS ANGELES, CA, May 21, 2026 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before de…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Immix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing - - No relapses to-date observed for patients who have reached CR - - All subsequently enrolled patients for who…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - Full enrollment of BLA-enabling trial complete, per prior guidance - - Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch - - Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission - LOS ANGELES, March 30, 2026 (GLOBE …
Read attachment ↗